Biocon Ltd. announces a new order win

The settlement does not disclose a specific calendar launch date or an explicit “at-risk” entry window. Biocon disclosed only the following earliest licensed launch windows under its 14 October 2026 global settlement with Genentech:

• European Union and UK: Q1 CY2027
• United States: Q3 CY2028
• Other RoW markets: CY2026–CY2028, with launch potentially earlier in certain circumstances
• Canada: covered by the global settlement, but no separate launch date was disclosed

The agreement’s other terms were confidential, and the company did not use “at-risk” terminology in the announcement. Therefore, these dates should be read as contractually permitted launch windows, not as proof that Biocon can launch before patent expiry without litigation exposure. ^[1]

Patent-expiry alignment

The timeline cannot be conclusively matched to key Perjeta patent expiry dates from the disclosed material. The U.S. litigation had identified two patent families—U.S. Patent Nos. 8,652,474 and 11,597,776 covering pertuzumab composition/formulation issues, and U.S. Patent Nos. 12,145,997 and 12,173,080 covering manufacturing processes—but the cited litigation summary does not provide their expiry dates, any patent-term adjustment, or applicable regulatory exclusivity period. ^[2]

Accordingly:

• EU/UK Q1 CY2027: broadly consistent with a post-settlement, licensed entry strategy, but alignment with European patent or supplementary protection certificate expiry is not verifiable from the disclosed terms.
• U.S. Q3 CY2028: likely reflects the negotiated resolution of the asserted U.S. patent disputes, but it cannot be described as matching patent expiry without the agreement’s patent schedule or expiry calculations.
• Canada and other markets: no market-specific dates or patent-expiry mapping were disclosed.

One additional execution caveat is that Pebrilzo had received a positive EMA CHMP opinion, but the European Commission still had to grant the marketing authorisation; until then, the product was not authorised for EU use. ^[3] Thus, Q1 CY2027 is a settlement-permitted target window, subject to the necessary regulatory authorisation and launch readiness, rather than a confirmed launch day.